A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane
- 6 October 2009
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (40) , 16996-17001
- https://doi.org/10.1073/pnas.0908444106
Abstract
Mutations in oncogenes often promote tumorigenesis by changing the conformation of the encoded proteins, thereby altering enzymatic activity. ThePIK3CAoncogene, which encodes p110α, the catalytic subunit of phosphatidylinositol 3-kinase alpha (PI3Kα), is one of the two most frequently mutated oncogenes in human cancers. We report the structure of the most common mutant of p110α in complex with two interacting domains of its regulatory partner (p85α), both free and bound to an inhibitor (wortmannin). The N-terminal SH2 (nSH2) domain of p85α is shown to form a scaffold for the entire enzyme complex, strategically positioned to communicate extrinsic signals from phosphopeptides to three distinct regions of p110α. Moreover, we found that Arg-1047 points toward the cell membrane, perpendicular to the orientation of His-1047 in the WT enzyme. Surprisingly, two loops of the kinase domain that contact the cell membrane shift conformation in the oncogenic mutant. Biochemical assays revealed that the enzymatic activity of the p110α His1047Arg mutant is differentially regulated by lipid membrane composition. These structural and biochemical data suggest a previously undescribed mechanism for mutational activation of a kinase that involves perturbation of its interaction with the cellular membrane.Keywords
This publication has 36 references indexed in Scilit:
- Wortmannin, an antibiotic produced by Penicillium wortmanniPublished by Elsevier ,2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomasVirchows Archiv, 2008
- Structural comparisons of class I phosphoinositide 3-kinasesNature Reviews Cancer, 2008
- Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanismsProceedings of the National Academy of Sciences, 2008
- PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parametersLaboratory Investigation, 2008
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- The Phosphoinositide 3-Kinase PathwayScience, 2002
- The CCP4 suite: programs for protein crystallographyActa Crystallographica Section D-Biological Crystallography, 1994